{"filing":{"accession_number":"0001193125-26-336670","cik":"0001658551","ticker":"AMLX","company_name":"Amylyx Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"amlx-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526336670/amlx-20260806.htm"},"events":[{"id":25534,"run_id":23177,"accession_number":"0001193125-26-336670","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Amylyx Pharmaceuticals issued a press release on August 6, 2026, announcing its financial results for the quarter ended June 30, 2026, disclosing R\u0026D expenses ($23.8M), SG\u0026A expenses ($21.9M), net loss ($43.4M or $0.39 per share), and cash position ($250.8M). The filing is made under Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for quarterly earnings disclosures.","company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26391,"accession_number":"0001193125-26-336670","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Amylyx Pharmaceuticals issued a press release on August 6, 2026, announcing its financial results for the quarter ended June 30, 2026, disclosing R\u0026D expenses ($23.8M), SG\u0026A expenses ($21.9M), net loss ($43.4M or $0.39 per share), and cash position ($250.8M). The filing is made under Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for quarterly earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:52:41.076793+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26391,"accession_number":"0001193125-26-336670","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Amylyx Pharmaceuticals issued a press release on August 6, 2026, announcing its financial results for the quarter ended June 30, 2026, disclosing R\u0026D expenses ($23.8M), SG\u0026A expenses ($21.9M), net loss ($43.4M or $0.39 per share), and cash position ($250.8M). The filing is made under Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for quarterly earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:52:41.076793+00:00","company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","filing_date":"2026-08-06"}]}